Drug Approval | June 14, 2024
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Subscribe To Our Newsletter & Stay Updated
